Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults

Newswire.ca - Fri Feb 6, 2:19PM CST

MONTREAL, Feb. 6, 2026 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that Health Canada has granted market authorization for Yorvipath® (palopegteriparatide injection), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of chronic hypoparathyroidism in adults. Yorvipath®, was developed by Ascendis Pharma A/S (NASDAQ: ASND) ("Ascendis").

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).